Navigation Links
Arterial in Medical Technology

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

... to clinical worsening in patients with pulmonary arterial hypertension (PAH)(1). The randomized, ... study entitled, "Tadalafil Therapy for Pulmonary arterial Hypertension," were published in today's issue of ... N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

... for Treatment of Lower Extremity Peripheral arterial Disease PLYMOUTH, Minn., April 30 ... treatment of lower extremity peripheral arterial disease (PAD). Stuart Harlin, M.D., of Sacred ... About Peripheral Artery Disease Peripheral arterial disease (PAD) occurs when leg arteries become ...

BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease

... using the EndoPAT device to assess peripheral arterial tonometry (PAT), was common in the sickle cell ... of Hematology Conference Abstract: Peripheral arterial Tonometry Assessment of Endothelial Dysfunction ... disease, peripheral arterial disease, coronary arterial disease and pulmonary hypertension, and has been ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment ... imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood ... . 3. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005 ...

Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)

... investigating TSC as a treatment for peripheral arterial disease (PAD) patients who experience the severe ... trials. About Multi-Center Trial in Peripheral arterial Disease Patients: This randomized, ... Website. About Peripheral arterial Disease and Intermittent Claudication: ...

Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease

... outcome. Notes to editor About Pulmonary arterial Hypertension (PAH) PAH is a syndrome ... and patients. About Tracleer(R) in Pulmonary arterial Hypertension (PAH) Tracleer(R) is an oral dual ... of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a ...

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering

... patients with hypertension as measured by arterial wall to lumen ratio (W/L), returning arterial architecture to normal levels after one year ... EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in ...

Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations

... G, et al. 2007 Guidelines for the Management of arterial Hypertension. The Task Force for the Management of arterial Hypertension of the European Society of ... G, et al. 2007 Guidelines for the Management of arterial Hypertension. The Task Force for the ...

Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report

... the clinical significance of peripheral arterial lesions, thus reducing the risk of ... this hypothesis in patients with peripheral arterial occlusive disease. "We've long suspected that ... Using this low profile PressureWire for arterial pressure measurement yields a more accurate ...

High Blood Pressure May Heighten Effects of Alzheimer's Disease

... For the study, the researchers used arterial spin-labeled magnetic resonance imaging (MRI), ... flow in the brain, to image 68 older adults. arterial spin-labeled MRI is a novel, ... flow in people with Alzheimer's disease. -- arterial spin-labeled MRI is a novel, noninvasive imaging ...

Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels

... in human tissue in vitro and in vivo. arterial plaques are associated with an array of ... exquisite compositional detail, in vivo, of arterial wall constituents and will be entering clinical ... analyze and quantify the chemical composition of arterial plaque and assess its vulnerability to rupture. ...

Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension

... therapy for the treatment of pulmonary arterial hypertension (PAH). Data from both studies ... mortality in symptomatic PAtientS with pulmonary arterial hypertenSion) was the first clinical trial ... as a monotherapy. About Tracleer(R) in Pulmonary arterial Hypertension (PAH) Tracleer(R) (bosentan), the ...

CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference

... improvements in neointimal proliferation, arterial injury, arterial inflammation, and reendothelialization when ... to maximize biocompatibility while minimizing arterial injury, potentially providing both short and ...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... Limited (TSE: 4568) as a potential treatment for the prevention of both arterial and venous thromboembolism; a Phase III trial is underway among patients ... edoxaban as a potential new treatment for the prevention of both arterial and venous thromboembolism. Notably, Daiichi Sankyo has more than 25 ...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

... Angiotensin II is a hormone that interacts with a receptor on arterial blood vessels, which results in constriction and increasing blood ... Society of Cardiology 2007 Guidelines for the Management of arterial Hypertension. Available at: ...

New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery

... blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's ... the ability to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... with prior MI or stroke, as well as patients with existing peripheral arterial disease. Patients will be randomized to either placebo plus standard ... infarction or stroke, as well as in patients with existing peripheral arterial disease. The U.S. Food and Drug Administration (FDA) had previously ...

For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold

... patients' other medical conditions -- such as whether they had peripheral arterial disease (PAD) or diabetes, whether they were smokers and whether they used ... stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern ...

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults

... (CML) in older adults is associated with a decline in renal function and arterial stiffness in older adults. Kits developed through a license to Synvista's ... that elevated levels of CML in these subjects corresponded to increased arterial stiffness, a known predictor of cardiovascular disease. The ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... of the study was the combined occurrence of clinically overt venous or arterial thromboembolic events (i.e., deep-vein thrombosis of the lower and upper ... embolism, acute myocardial infarction, ischemic stroke, acute peripheral arterial thromboembolism, and unexplained death of possible thromboembolic origin). ...

New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration

... inhaled formulation of treprostinil (ITRE) for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disease. The submission ... (TReprostinil Sodium Inhalation Used in the Management of Pulmonary arterial Hypertension), was a randomized, double-blind, placebo- controlled trial ...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

... that data from seven presentations concerning the treatment of pulmonary arterial hypertension (PAH) with treprostinil were reported at the American ... (TReprostinil Sodium Inhalation Used in the Management of Pulmonary arterial Hypertension) trial was a randomized, double-blind, placebo-controlled ...

Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension

... acting as partial dopamine agonist on the pituitary. About Pulmonary arterial hypertension Pulmonary arterial hypertension is a disorder of the blood vessels in the lung, in which the ...

Large Study Gives Nod to Drug-Eluting Stents in Heart Attack

... arterial renarrowing less likely, with no increase in mortality on ... database. The analysis showed a significantly lower risk of arterial renarrowing, or restenosis, among heart attack patients who were treated ...

Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease

... in the treatment of intermittent claudication, associated with peripheral arterial disease (PAD). The results demonstrated that treatment for two months with ... course of vascular disease potentially by increasing inflammation in the arterial wall thus leading to exacerbation of atherosclerosis, which could reduce ...

Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007

... 3 trial of Viveta, an inhaled formulation of treprostinil, in pulmonary arterial hypertension (PAH) before market open on Thursday, November 1, 2007. ... (TReprostinil Sodium Inhalation Used in the Management of Pulmonary arterial Hypertension), was a randomized, double-blind, placebo- controlled trial ...

ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting

... in the treatment of intermittent claudication associated with peripheral arterial disease (PAD) will be presented on November 7, 2007 at 11:45 a.m. EST at a ... course of vascular disease potentially by increasing inflammation in the arterial wall thus leading to exacerbation of atherosclerosis, which could reduce ...

Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg

... - arterial Blockages in the Leg are Estimated to Affect 8 Million Americans ... stent versus balloon angioplasty alone in treating peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal ...

Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore

... (dispensing), stents can benefit patients who suffer from peripheral arterial disease (PAD) is taking place at Montefiore Medical Center, one of only 80 ... gangrene and amputation. It also may signal an increased risk for coronary arterial disease and other related circulatory conditions. "This is an exciting ...

Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance

... coronary artery disease and helps exclude patients without coronary arterial disease with a high negative predictive value (NPV). Rcadia's COR Analyzer ... read, alerting the reader which patients are most likely to have coronary arterial disease. Since COR Analyzer automatically marks pathologies; this in turn ...

Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety

... patients in the bare metal stent arm to need another procedure in the same arterial area (TLR or target lesion revascularization). In addition, the ... nearly 76 percent less likely to require a second procedure in the same arterial area within five years than a patient who was implanted a bare metal stent ...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

... the risks of cardiovascular disease in older adults. Cardiovascular disease caused by atherosclerosis, or the build-up of plaques along the arterial wall, is the greatest single killer of American women--40% of total deaths--and the rate of mortality is nearly as high for men. Atherosclerosis can ...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 ...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

... leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 ...

Glybera(TM) Shows Long-Term Health Benefits

... and mortality. These data were presented at the International Symposium on Atherosclerosis in Boston, one on the most prestigious conferences on arterial disease well-attended by expert physicians. The three year follow-up data for the eight patients from the first clinical trial show a ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... after various systemic therapies or who were no longer candidates for local therapies, including surgery, percutaneous ablation or transcatheter arterial chemoembolization. Of the 31 patients evaluable in the trial, 16 received everolimus (known as RAD001 in this study) daily. The study objective was ...

Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting

... of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc. ...

FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension

... administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of ...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

... M.D., at Trinity Terrace Park Hospital in Bettendorf, Iowa. "Peripheral stenting has become a recognized standard in the treatment of iliac arterial disease," said Daniel Clair, M.D., FACS, Principal Investigator of the trial and Chairman of the Department of Vascular Surgery, The Cleveland Clinic ...

Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data

... the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral arterial Disease (PAD). These milestones include the selection of physician investigators for U.S. clinical trials and the completion of a new ...
Other Contents
(Date:9/16/2014)... The risk of severe maternal morbidity amongst women ... suggests a new study published today (17 September) ... and Gynaecology . , Australians generally enjoy high ... that health disparities exist, in particular between indigenous ... aimed to explore the independent impact of socioeconomic ...
(Date:9/16/2014)... YORK (17 September, 2014)More than $100 trillion in ... of annual carbon dioxide (CO2)a 40 percent reduction ... 2050 if the world expands public transportation, walking ... report released by the University of California, Davis, ... (ITDP). , Further, an estimated 1.4 million ...
(Date:9/16/2014)... Pit Fire began on September 13, 2014. The fire ... is currently over 2,300 acres in size and is mostly ... Pit Fire was calm Monday night due to higher humidity. ... anchor point and beginning to construct a fireline on the ... resources are working on the fire: , 7 20-person Crews, ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
(Date:9/17/2014)... (PRWEB) September 17, 2014 With ... have special functions of adjusting human body physiology, ... won great popularity with a variety of specific ... food in China reached RMB187.4 billion, up 12.0% ... during 2006-2013. , China's health product industry is ...
(Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
(Date:9/17/2014)... 17, 2014 Researchers say patients with ... least likely to have good outcomes with chemotherapy treatment. ... findings. Click here to read it now. ... Levine Cancer Institute in North Carolina analyzed 30 published ... the 137 patients with sarcomatoid mesothelioma had ...
(Date:9/17/2014)... 17, 2014 There’s something changing ... girls of all ages an all-natural option for ... by women, for women, announces the launch of ... to relieve the symptoms commonly associated with ... , As a lifelong health enthusiast and ...
(Date:9/17/2014)... September 17, 2014 Request A Test ... testing, is offering 10% off drug testing through ... all drug tests, including those ordered by employers for workplace ... advantage of this discount by using promo code DRUG10 when ... in positives on workplace drug testing, especially for marijuana or ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Doctors Find Lower Treatment Response in Those with Rare Type of Mesothelioma, According to Surviving Mesothelioma 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:Request A Test Can Save You 10% on Drug Testing 2Health News:Request A Test Can Save You 10% on Drug Testing 3
Other TagsOther Tags